Proteomic biomarkers and biological pathways associated with atrial fibrillation in heart failure patients with reduced ejection fraction
Patients with HFrEF with AF have distinct circulating proteomic profiles, and these differences are related to various biological mechanisms. This study provides an overview of the systemic biological pathways associated with AF in patients with HFrEF, confirms (pre-)clinical findings regarding AF-related proteins, and could inform future research in novel treatment targets and HFrEF-AF management after careful validation.
Authors
- Bas M. van Dalen (ORCID: https://orcid.org/0000-0002-8294-7008)
- Jasper J. Brugts (ORCID: https://orcid.org/0000-0002-5522-9318)
- Teun B. Petersen (ORCID: https://orcid.org/0000-0002-2338-9931)
- Peter D. Katsikis (ORCID: https://orcid.org/0000-0001-7690-5218)
- Victor A. Umans (ORCID: https://orcid.org/0000-0002-5587-9097)
- Rudolf A. de Boer (ORCID: https://orcid.org/0000-0002-4775-9140)
- K. Martijn Akkerhuis (ORCID: https://orcid.org/0000-0003-4833-3130)
- Sing‐Chien Yap (ORCID: https://orcid.org/0000-0003-4520-2725)
- Navin Suthahar (ORCID: https://orcid.org/0000-0002-7781-2897)
- Isabella Kardys (ORCID: https://orcid.org/0000-0002-2115-9745)
- Peter J. van der Spek (ORCID: https://orcid.org/0000-0002-2203-0652)
- Dimitris Rizopoulos (ORCID: https://orcid.org/0000-0001-9397-0900)
- Mylène Barry‐Loncq de Jong
- Jie Fen Chin
- Eric Boersma (ORCID: https://orcid.org/0000-0003-1159-7802)
- Folkert W Asselbergs
Institutions
- Erasmus MC (NL)
- Sint Franciscus Gasthuis (NL)
- Northwest Hospital (US)
- Erasmus MC Cancer Institute (NL)
- Amsterdam University Medical Centers (NL)
- University of Amsterdam (NL)
- Erasmus University Rotterdam (NL)
Publication Details
- Journal
- Heart Rhythm O2
- Published
- 2025-06-16
- DOI
- https://doi.org/10.1016/j.hroo.2025.06.007
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- AstraZeneca
- Sanofi
- Boston Scientific Corporation
- European Federation of Pharmaceutical Industries and Associations
- National Institute for Health and Care Research
- Jaap Schouten Foundation